NCT07085104

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2025-11-13Est. Completion: 2028-02

Enrollment target: 66 participants

Locations

Mayo Clinic, Phoenix, Arizona, United States
Loma Linda University Medical Center, Loma Linda, California, United States
University of Colorado Denver, Aurora, Colorado, United States
Mayo Clinic, Jacksonville, Florida, United States
The University of Chicago Medical Center, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
Astera Cancer Care, East Brunswick, New Jersey, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Prisma Health, Greenville, South Carolina, United States
LDS Hospital - lntermountain Health, Salt Lake City, Utah, United States
Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada

Systemic Lupus Erythematosus (Sle)Primary Ovarian Insufficiency (Poi)

Background: Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. Peop…

Bethesda, United StatesEst. completion May 31, 2027

Systemic Lupus Erythematosus (SLE)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic…

Phoenix, United StatesCompleted Mar 29, 2030

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.